Highlight
– More than 60% of global liver cancer cases are preventable, but the incidence is projected to double by 2050 due to rising obesity and metabolic liver disease.
– The Lancet Commission identifies metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, MASH, as key drivers of future hepatocellular carcinoma (HCC) burden.
– Ten actionable recommendations target viral hepatitis, alcohol use, obesity, environmental risks, and healthcare disparities to reduce new cases and deaths.
– Achieving an annual 2–5% reduction in new cases could prevent up to 17 million liver cancers and 15 million deaths by 2050.
